Airway hyperreactivity (AHR), eosinophilic inflammation with a Th2-type cytokine profile, and specific Th2-mediated IgE production characterize allergic asthma. In this paper, we show that OVA-immunized J␣18 ؊/؊ mice, which are exclusively deficient in the invariant V␣14 
transfer of effector Th2 cells into naive mice followed by exposure to inhaled Ags triggers eosinophilic inflammation, mucus hypersecretion, and airway hyperresponsiveness, definitively demonstrating the capacity of immune Th2 cells to induce the asthma phenotype (3) . It is generally known that rapid generation of IL-4 supports the crucial Ag-specific Th2 cell differentiation. The exact source of this required IL-4 is not known, but besides Th2 cells themselves, cells like mast cells, basophils, ␥/␦ T cells, and NKT lymphocytes are thought to be contributors to Th2 immune responses.
NKT cells are a distinct subset of lymphocytes with NK markers and ␣␤ TCR, that regulate immune responses in several models of autoimmunity, infection, and cancer (4) . They are selected and are restricted by the nonpolymorphic MHC class I-like molecule, CD1d, and express an invariant V␣14 (iV␣14)-J␣18 TCR chain (4, 5) . Since the stimulation of their TCR by glycolipid ligands, such as exogenous ␣-galactosylceramide (␣-GalCer) presented in the context of CD1d molecules, promptly induces secretion of high concentrations of IL-4 (6), it has been proposed that they may participate in the differentiation of Th2 cells. Indeed, ␣-GalCer-stimulated NKT lymphocytes, in some cases, promote a protective Th2 immune response (7, 8) . However, even though Th2 differentiation can be accomplished normally in NKT cell-deficient mice (9, 10) , it cannot be excluded that NKT cells influence the development of some immune responses involving Th2 cells.
In the present study, we demonstrate that the iV␣14 NKT cell subset is required for airway eosinophilia, hyperresponsiveness, Th2 cytokine production, and elevated levels of IgE Abs, in an experimental model of allergic asthma.
Materials and Methods

Mice
Six-to 8-wk-old male C57BL/6 wild-type (WT) and J␣18 Ϫ/Ϫ (backcrossed at least 10 times in C57BL/6) (11) mice were bred in our own facilities. All mice were kept in well-controlled animal housing facilities and had free access to tap water and pellet food throughout the experimental period.
Ag immunization and airway challenge
At 1-wk intervals animals were immunized by an i.p. (day 0) and a s.c. (day 7) injection with 4 g OVA (ICN Biomedicals) adsorbed on 1.6 mg of aluminium hydroxide gel (Merck, Darmstadt, Germany) in 0.4 ml of sterile saline. Beginning on day 14 following the initial immunization, mice were anesthetized with ketamine anesthesia (Imalgene 1000, 35 mg/kg; Merial, Lyon, France) and airway challenged twice (days 14 and 21) intranasally with 10 g of OVA in 50 l of saline. Control mice received only saline at these times. Twenty-four hours after the last intranasal challenge (day 22), each group consisting of 6 -20 mice was analyzed for eosinophil infiltration, airway hyperresponsiveness, cytokine levels, and Ab production.
In some experiments, at 1-wk intervals, animals were immunized by three i.p. injections (days 0, 7, and 14) with 10 g OVA adsorbed on 1.6 mg of aluminum hydroxide gel in 0.4 ml of sterile saline. Sera were collected on day 15 and storaged for IgE measurement.
Adoptive transfer
Spleen cells from WT or J␣18
Ϫ/Ϫ mice were depleted of CD8 ϩ T cells, CD62L
ϩ , and CD19 ϩ B cells labeled with the corresponding mAbs with antirat Ig-coated magnetic beads (Dynal, Compiègne, France). Among the mAbs used for cell depletion CD8 (clone 53.67) and CD62L (clone Mel14) were purified in our laboratory while the anti-CD19 (clone 1D3) was purchased from BD PharMingen (San Diego, CA). The enriched negative selected NKT spleen cell population (containing 10 5 iV␣14 NKT cells, as assessed by CD1d/ ␣-GalCer tetramers staining), as well as a negative control (equivalent numbers of similarly depleted spleen cells from J␣18 Ϫ/Ϫ mice) were injected i.v. into J␣18 Ϫ/Ϫ mice that had been immunized twice with OVA.
Blocking of NKT/CD1d cell interaction in vivo
In some experiments, in addition to OVA immunization and challenge (as described above), separate groups of mice were also treated i.p. with 0.15 mg of blocking rat anti-CD1d mAb (clone 20H2) or control rat IgG (Sigma-Aldrich, Stonheim, Germany) per mouse on days Ϫ1, 0, ϩ2, ϩ6, ϩ7, ϩ9, ϩ13, ϩ14, ϩ16, ϩ20, and ϩ21. No differences in the percentage of iV␣14 NKT splenocytes were observed following anti-CD1d or Ig treatment on day 22 when mice were sacrificed (data not shown).
Determination of airway hyperresponsiveness
Airway responsiveness was assessed as previously described (12) . Briefly, 24 h after the last challenge, conscious mice were placed into a plethysmograph chamber (Buxco Eletronics, Sharon, CT), and respiratory parameters were measured after 10 min of aerosol administration of 150 mM methacholine (Sigma-Aldrich) delivered for 60 s. Airflow obstruction was expressed as enhanced pause ( 
Bronchoalveolar lavage fluid (BALF)
Immediately after assessment of AHR, mice were deeply anesthetized by i.p. injection of urethane (15 mg/10 g body weight) (Sigma-Aldrich), blood was collected, and the resulting serum was stored. Airways were washed twice with saline, and the BALF cell differential counts and percentages were determined by Diff-Quik (Baxter-Dale, Dudingen, Germany) staining of cytospin slides. Two-hundred cells per slide were counted. Aliquots of BALF were stored for cytokine measurement.
Determination of cytokines in BALF and of serial OVA-specific IgE
The levels of IL-4, IL-5, IL-13, and IFN-␥ in BALF and OVA-specific IgE serum levels were assessed by ELISA as previously described (6, 12) OVA-specific IgE levels of samples were related to an internal standard from pooled sera of hyperimmunized BALB/c mice. 
Flow cytometric analysis
Kinetic analysis of NKT cell activation after exposure to OVA was performed.
In brief, 24 h after immunizations and/or intranasal challenges, mice were sacrificed, and splenocytes were recovered and stained for 30 min in PBS containing 2% FCS and 0.01 M sodium azide and mCD1d-␣-GalCer tetramer-APC. Tetramers were prepared in our laboratory from mCD1d/m␤2m expression vector (13) . Cells were then incubated with appropriate dilutions of anti-CD4 PerCP-Cy-5.5 (clone RM4-5), anti-TCR␣␤-FITC (clone H57-597) and anti-CD69-PE (H1.2F3), all purchased from BD PharMingen. Dead cells were excluded on the basis of forward and side scatter. At least 5 ϫ 10 5 live lymphoid cells were acquired in each run. Samples were analyzed on a FACSCalibur (BD Biosciences, Mountain View, CA) using CellQuest software.
Statistical analysis
Nonparametric Mann-Whitney test was used to calculate significance levels for all measurements. Values of p Ͻ 0.05 was considered statistically significant.
Results
AHR and eosinophilic inflammation is reduced in J␣18
Ϫ/Ϫ mice
Marked features in this model of allergen-induced asthma are AHR and massive airway inflammation observed following OVA challenge. Our findings clearly demonstrate that OVAsensitized and -challenged J␣18 Ϫ/Ϫ mice developed decreased AHR after methacholine inhalation as compared with OVAsensitized and -challenged control mice ( Fig. 1) , implicating iV␣14 NKT cells in AHR. The total cell number in BALF of J␣18 Ϫ/Ϫ mice following two intranasal OVA challenges was decreased by 42% compared with WT mice (Fig. 2A) . The percentage of eosinophils, which account for the majority of cells in BALF from OVA-challenged mice (up to 65%), was decreased by 58% in iV␣14 NKT cell-deficient animals (Fig. 2B) . Both macrophages and neutrophils also were reduced accounting for the overall decrease (2.6 Ϯ 0. mice, respectively). Conversely, lymphocyte recruitment in BALF was not modified 7 Ϯ 2 ϫ 10 3 vs 4.7 Ϯ 2 ϫ 10 3 lymphocytes/ml in OVA-challenged WT and J␣18 Ϫ/Ϫ mice, respectively). Among these lymphocytes, iV␣14 NKT cells were also recruited to the lung of OVA-treated WT mice as assessed by RT-PCR analysis (data not shown).
Both IL-4 and IL-5 production are impaired in BALF of immunized J␣18
Ϫ/Ϫ mice IL-4 and IL-5 levels were markedly reduced in BALF collected 24 h after challenge from NKT cell-deficient mice as compared with WT littermates (Fig. 2, C and D) . Impaired IL-5 production FIGURE 1. Decreased AHR development in J␣18 Ϫ/Ϫ mice. Airway reactivity to methacholine was measured 1 day after the last challenge with OVA (E and Ⅺ) or NaCl (F and f) in both WT (squares) and J␣18
Ϫ/Ϫ (circles) mice. Data represent the mean Ϯ SEM Penh values from 6 to 20 mice. in response to OVA challenge was also observed in the serum of J␣18 Ϫ/Ϫ mice (Fig. 2E) , showing a systemic defect in the production of this cytokine in the absence of NKT cells. IL-4 levels in the serum were below detection limits (Ͻ10 pg/ml).
OVA-specific IgE secretion is markedly decreased in J␣18
Ϫ/Ϫ mice To assess the peripheral response to immunization and subsequent allergen challenge, we measured OVA-specific IgE levels in the sera using ELISA. OVA-immunized and -challenged J␣18 Ϫ/Ϫ mice had one-eighth (12.3 Ϯ 9.7%) OVA-specific IgE compared with WT littermates, indicating that IgE production was severely affected (Fig. 2F) . The failure to produce high levels of anti-OVA IgE was not due to the inability of J␣18 Ϫ/Ϫ mice to produce this isotype, because in response to three OVA immunizations but without intranasal challenges they did effectively produce anti-OVA IgE (0.83 Ϯ 0.10 and anti-OVA IgE titer for J␣18 Ϫ/Ϫ and 1.53 Ϯ 0.22 for WT mice).
Adoptive transfer of iV␣14 NKT cells restores AHR development, airway eosinophilia, as well as IL-4, IL-5, and IgE production in J␣18
To confirm the implication of iV␣14 NKT cells in the severity of allergic asthma, we reconstituted OVA-sensitized J␣18
Ϫ/Ϫ mice with iV␣14 NKT lymphocytes 24 h before the first OVA airway challenge. Adoptive transfer of iV␣14 NKT cells, but not of spleen cells from J␣18 Ϫ/Ϫ mice, fully restored the capacity of J␣18 Ϫ/Ϫ mice to develop AHR (Fig. 3A) . Moreover, airway eosinophilia (Fig. 3B) , both IL-4 ( Fig. 3C ) and IL-5 ( Fig.  3D ) production in the BALF as well as specific anti-OVA IgE (Fig. 3E ) in the serum of OVA-sensitized and -challenged J␣18 Ϫ/Ϫ mice were restored by the adoptive transfer of iV␣14 NKT cells.
iV␣14 NKT cells are activated in OVA-treated mice
We evaluated whether iV␣14 NKT lymphocytes were activated during OVA-induced allergic asthma, as assessed by expression of the early activation marker CD69. Indeed, CD69 expression was up regulated on tetramer CD1d/␣-GalCer ϩ TCR␣␤ ϩ splenocytes from OVA-immunized and -challenged mice on day 21 compared with those immunized with OVA but challenged with NaCl (Fig. 4A) , demonstrating the activation of these cells following the OVA treatments. Similar results were obtained on day 14 after the first OVA challenge (data not shown).
iV␣14 NKT cells mediate Th2 allergen-induced airway inflammation in a CD1d-dependent manner
We have previously reported that NKT activation of iV␣14 ϩ NKT cells does not necessarily occur in a CD1d-dependent manner, but can also be induced by the pro-inflammatory cytokines IL-12 and IL-18 (14) . To evaluate possible CD1d involvement in NKT cell participation in Th2 asthmatic responses, WT mice were treated with blocking anti-CD1d mAb, or with control rat IgG at several time points during OVA immunization and challenge. Fig. 4B clearly shows that antiCD1d treatment prevents the characteristic eosinophil recruitment to BALF observed after OVA challenge. Similarly, the secretion of both IL-4 ( Fig. 4C) and IL-5 (Fig. 4D ) levels in the BALF and of specific serum anti-OVA IgE Abs (Fig. 4E) were diminished when CD1d-dependent interactions were blocked.
Discussion
Our experiments with J␣18 Ϫ/Ϫ mice clearly show that iV␣14 NKT lymphocytes are required for the characteristic features of experimental allergic asthma, namely airway inflammation, BALF Th2 cytokine production and the secretion of high levels of specific anti-OVA IgE, that will ultimely induce AHR.
The failure of J␣18 Ϫ/Ϫ mice to develop the typical Th2 inflammation, AHR and IgE responses following OVA airway challenge is not due to a deficiency in Th2 responsiveness since these mice produce high levels of IgE in another protocol using three systemic immunizations with 2.5 higher doses of OVA. These data concur with previous reports showing that J␣18 Ϫ/Ϫ mice are not defective in IgE production (15) . In this study we used a protocol where all mice were similarly immunized with OVA and alum, and airway OVA challenge resulting in Th2 inflammation and AHR. Because we found that iV␣14 NKT cells are present in the lung of OVA-challenged mice, it is possible that they are involved during challenge rather than necessarily during priming. According to this postulate, we adoptively transferred WT iV␣14 NKT cells just before OVA challenge, and then sufficed to restore the capacity of J␣18 Ϫ/Ϫ mice to fully develop airway eosinophilia, AHR, BALF cytokine, and anti-OVA IgE production.
Our results differ from those of a previous study using another type of NKT cell-deficient mice, lacking CD1d molecules (16) , which demonstrated that allergen-specific IgE levels and eosinophilia were not different from those observed in WT mice. Discrepancies observed may be explained by the different experimental protocols (two vs multiple challenges, timing of mice sacrifice) as well as the genetic background of the mutant mice (129/Sv ϫ C57BL/6 for CD1d Ϫ/Ϫ and C57BL/6 for J␣18 Ϫ/Ϫ mice). It is unlikely that the genotype (CD1d Ϫ/Ϫ vs J␣18 Ϫ/Ϫ mice) is responsible for these differences since CD1d Ϫ/Ϫ mice (backcrossed with C57BL/6) and J␣18
Ϫ/Ϫ mice were similarly deficient in response to our protocol of immunization and challenge (data not shown). Moreover, in agreement with our results, it has recently been reported that both CD1d Ϫ/Ϫ and J␣18 Ϫ/Ϫ mice, backcrossed with BALB/c, develop neither AHR nor airway eosinophilia, Th2 cytokine production and high levels of IgE following OVA challenge (17) . Taken together, these results clearly demonstrate the requirement of iV␣14 NKT cells in allergen-induced asthma.
Additionally, our findings show that iV␣14 NKT cells are present in lungs of OVA-treated mice, that they are systemically activated (up-regulation of CD69), and that their implication in this model is mediated through CD1d interactions. We and others have already demonstrated that NKT cells stimulated with ␣-GalCer favor Th2 or Th1 protective immune responses in experimental autoimmune diseases or tumors, respectively (4) . In contrast, the present study underscores the capacity of activated iV␣14 NKT cells to mediate a pathological Th2 allergy immune response in asthma. It is probable that this activation involves recognition of endogenous Ags associated with CD1d molecules, because OVA itself was unable to stimulate NKT cells neither from naive nor from OVA-treated mice (day 22) (data not shown). Endogenous Ags capable of stimulating iV␣14 NKT cells remain to be determined, but it has been suggested that the self-Ags, presumably glycolipids, that bind CD1d are recognized by V␣14 ϩ TCR of these cells. In conclusion, we have demonstrated that iV␣14 NKT cells mediate Th2 eosinophil airway inflammation and AHR in an allergen-induced asthma model. Thus, NKT cells may mediate or amplify the pathogenic Th2 inflammatory response and crucial AHR in allergic asthma, suggesting that depletion or blockade of NKT cells might be a possible option for the treatment of this disease.
